Pharming Group N.V.
PHGUF
$1.24
-$0.01-0.58%
OTC PK
| 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -8.40% | 14.96% | 25.82% | 25.82% | 42.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.40% | 14.96% | 25.82% | 25.82% | 42.29% |
| Cost of Revenue | -20.17% | 73.05% | 12.42% | 12.42% | -0.75% |
| Gross Profit | -7.02% | 6.14% | 27.43% | 27.43% | 49.94% |
| SG&A Expenses | -20.19% | 8.82% | 17.93% | 17.93% | 25.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.57% | -143.36% | -102.74% | -102.74% | -11.01% |
| Total Operating Expenses | -10.19% | 27.87% | 16.78% | 16.78% | 19.81% |
| Operating Income | 30.28% | -74.18% | 197.69% | 197.69% | 56.82% |
| Income Before Tax | 59.67% | -28.12% | 11,898.33% | 11,898.33% | 29.09% |
| Income Tax Expenses | -85.19% | -113.83% | 118.39% | 118.39% | 174.23% |
| Earnings from Continuing Operations | 64.99% | 86.36% | 473.56% | 473.56% | -19.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.58% | 86.36% | 485.39% | 485.39% | -18.24% |
| EBIT | 30.28% | -74.18% | 197.69% | 197.69% | 56.82% |
| EBITDA | 59.77% | -67.91% | 465.16% | 465.16% | 57.06% |
| EPS Basic | 68.18% | 105.13% | 477.78% | 477.78% | -15.79% |
| Normalized Basic EPS | 62.96% | -84.85% | -300.00% | -300.00% | -- |
| EPS Diluted | 68.18% | 105.71% | 466.67% | 466.67% | -15.79% |
| Normalized Diluted EPS | 62.96% | -86.87% | -300.00% | -300.00% | -- |
| Average Basic Shares Outstanding | 11.31% | -10.47% | -0.37% | -0.37% | 2.12% |
| Average Diluted Shares Outstanding | 11.31% | 2.32% | -0.37% | -0.37% | 2.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |